JP2012532879A5 - - Google Patents

Download PDF

Info

Publication number
JP2012532879A5
JP2012532879A5 JP2012519703A JP2012519703A JP2012532879A5 JP 2012532879 A5 JP2012532879 A5 JP 2012532879A5 JP 2012519703 A JP2012519703 A JP 2012519703A JP 2012519703 A JP2012519703 A JP 2012519703A JP 2012532879 A5 JP2012532879 A5 JP 2012532879A5
Authority
JP
Japan
Prior art keywords
cancer
itpp
effective amount
therapeutically effective
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012519703A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012532879A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/041250 external-priority patent/WO2011005886A1/en
Publication of JP2012532879A publication Critical patent/JP2012532879A/ja
Publication of JP2012532879A5 publication Critical patent/JP2012532879A5/ja
Pending legal-status Critical Current

Links

JP2012519703A 2009-07-07 2010-07-07 イノシトールトリピロリン酸を使用して多剤耐性を低減する方法 Pending JP2012532879A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22358309P 2009-07-07 2009-07-07
US61/223,583 2009-07-07
PCT/US2010/041250 WO2011005886A1 (en) 2009-07-07 2010-07-07 Method of reducing multi-drug resistance using inositol tripyrophosphate

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015127462A Division JP2015166393A (ja) 2009-07-07 2015-06-25 イノシトールトリピロリン酸を使用して多剤耐性を低減する方法

Publications (2)

Publication Number Publication Date
JP2012532879A JP2012532879A (ja) 2012-12-20
JP2012532879A5 true JP2012532879A5 (https=) 2013-08-29

Family

ID=43429524

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012519703A Pending JP2012532879A (ja) 2009-07-07 2010-07-07 イノシトールトリピロリン酸を使用して多剤耐性を低減する方法
JP2015127462A Pending JP2015166393A (ja) 2009-07-07 2015-06-25 イノシトールトリピロリン酸を使用して多剤耐性を低減する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015127462A Pending JP2015166393A (ja) 2009-07-07 2015-06-25 イノシトールトリピロリン酸を使用して多剤耐性を低減する方法

Country Status (7)

Country Link
US (3) US20120003327A1 (https=)
EP (1) EP2451459B1 (https=)
JP (2) JP2012532879A (https=)
CN (2) CN103495170A (https=)
MX (1) MX2012000383A (https=)
RU (1) RU2563127C2 (https=)
WO (1) WO2011005886A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140106004A1 (en) * 2012-10-12 2014-04-17 Bing Lou Wong Hemoglobin-based oxygen carrier-containing pharmaceutical composition for cancer targeting treatment and prevention of cancer recurrence
US20140274966A1 (en) * 2013-03-14 2014-09-18 Hygia Pharmaceuticals, Llc Drink Product Containing Genistein and Use Thereof
TWI771315B (zh) * 2016-08-26 2022-07-21 奧野哲治 微小奈米化藥劑及其利用
MX2019003895A (es) * 2016-10-04 2019-10-07 Asclepix Therapeutics Inc Compuestos y metodos para activar la señalizacion tie2.
MA51276A (fr) * 2017-12-22 2021-04-21 Lo Li Pharma Srl Traitement de la fibrose avec de l'inositol
US20210361680A1 (en) * 2018-05-03 2021-11-25 Normoxys, Inc. Inositol-based immunotherapies
TWI686210B (zh) 2018-06-01 2020-03-01 國立清華大學 用以誘導病變組織血管正常化的套組及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9002278L (sv) * 1990-06-28 1991-12-29 Perstorp Ab Anvaendning av inositoltrisfosfat foer framstaellning av ett laekemedel
US6632797B2 (en) * 1996-06-24 2003-10-14 Matti Siren Method of treating angiogenesis
JP3989997B2 (ja) * 1997-04-08 2007-10-10 ポーラ化成工業株式会社 放射線増感剤の製造方法
US6153603A (en) * 1997-06-27 2000-11-28 Perstorp Ab Method of treating angiogenesis in tumor tissue
US6890904B1 (en) * 1999-05-25 2005-05-10 Point Therapeutics, Inc. Anti-tumor agents
JP4116793B2 (ja) * 1999-09-13 2008-07-09 良尋 高井 新規ニトロイミダゾール誘導体及びこれを含む画像診断薬
US7084115B2 (en) * 2002-04-29 2006-08-01 Oxyplus, Inc. Inositol pyrophosphates, and methods of use thereof
US20060258626A1 (en) * 2004-07-06 2006-11-16 Claude Nicolau Use of inositol-tripyrophosphate in treating tumors and diseases
US20070166388A1 (en) * 2005-02-18 2007-07-19 Desai Neil P Combinations and modes of administration of therapeutic agents and combination therapy
PL1863495T3 (pl) * 2005-03-18 2015-06-30 Normoxys Inc Sól wapniowa 1,6:2,3:4,5-tripirofosforanu mioinozytolu jako efektor allosteryczny hemoglobiny w leczeniu raka
WO2007081315A1 (en) * 2006-01-06 2007-07-19 Oxyplus, Inc. Use of inositol-tripyrophosphate in treating tumors and diseases

Similar Documents

Publication Publication Date Title
JP2012532879A5 (https=)
Fan et al. Carrier-free, pure nanodrug formed by the self-assembly of an anticancer drug for cancer immune therapy
Sharma et al. A marine sponge alkaloid derivative 4-chloro fascaplysin inhibits tumor growth and VEGF mediated angiogenesis by disrupting PI3K/Akt/mTOR signaling cascade
Wang et al. Specific cell targeting with APRPG conjugated PEG–PLGA nanoparticles for treating ovarian cancer
FI3834882T3 (fi) Syövän hoitaminen käyttämällä sähkömagneettisia kenttiä yhdistelmänä muiden hoito-ohjelmien kanssa
Zhong et al. Targeting proinflammatory molecules using multifunctional MnO nanoparticles to inhibit breast cancer recurrence and metastasis
Yang et al. Responsively aggregatable sub-6 nm nanochelators induce simultaneous antiangiogenesis and vascular obstruction for enhanced tumor vasculature targeted therapy
CN102125717A (zh) 携带放射性粒子胆道内引流管
Zong et al. Ph-responsive pluronic F127–lenvatinib-encapsulated halogenated boron-dipyrromethene nanoparticles for combined photodynamic therapy and chemotherapy of liver cancer
CN107921047B (zh) 芳基喹啉衍生物作为血管生成拟态抑制剂的新用途
JP2007519609A5 (https=)
AU2014219129B2 (en) Caged platinum nanoclusters for anticancer chemotherapeutics
Das et al. Recent trends in the design and delivery strategies of ruthenium complexes for breast cancer therapy
Xiao et al. Recent advances of nanomaterial-based anti-angiogenic therapy in tumor vascular normalization and immunotherapy
RU2012104022A (ru) Способ уменьшения мультилекарственной резистентности с использованием трипирофосфата инозита
CN106459011A (zh) 作为抗肿瘤化合物的σ‑2受体配体药物缀合物、其合成方法及其用途
Peng et al. Traceable nanoparticles with mitochondria-targeting pyruvate-Cu induce cuproptosis for enhanced triple-negative breast cancer therapy in a mouse model
Shao et al. Strategies of porous network quinolone polymers: A comprehensive evaluation of their biological activity
Manatunga et al. Effective delivery of hydrophobic drugs to breast (MCF-7) and Liver (HepG2) cancer cells: a detailed investigation using cytotoxicity assays, fluorescence imaging and flow cytometry
Fu et al. A review: advances of curcumin co-delivery biomaterials-based system in anti-tumor therapy
Shaw et al. Cancer therapeutics strategy using nano-carrier mediated natural drugs
Wu et al. Mixed Nanoscale Liposomes Co-Encapsulating Curcumin and Berberine Inhibit Activated Hepatic Stellate Cell-Induced Drug Resistance and Tumor Metastasis
Matić et al. Synthesis of Nucleobase-Cyclam Conjugates and Transition Metal Complexes
CN105997978A (zh) 一种金属有机骨架化合物抗肿瘤血管生成剂及其使用方法
Abdelrahman et al. Breast cancer suppression by radiation prepared nanoformulation of Se@ Pt-AG-FA NPs through apoptotic pathway